Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 650 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... October 10, 2025 Middle Schooler Starts Business to Help Provide Spa and Salon Services... April 5, 2021 FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer... October 16, 2023 Learning to Live With Cancer: A Survivor’s Story November 30, 2023 Load more HOT NEWS Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... EMA Recommends Extension of Indications for Atezolizumab Let’s talk about HPV: 6 common questions answered
